BioLamina provides human recombinant laminin proteins that mimic the native extracellular matrix for improved cell culture. These biologically relevant substrates support robust cell expansion, differentiation, and maintenance, enhancing cell functionality and reproducibility for regenerative medicine and cell therapy development.
Funding
Funding not disclosed
Founders
Product
Problem
Standard cell culture methods often fail to replicate the complex extracellular matrix (ECM) environment found in vivo, leading to inconsistent cell behavior, reduced differentiation efficiency, and challenges in scaling for clinical applications. This lack of biological relevance hinders the development of robust cell-based therapies and accurate disease models.
Solution
BioLamina provides a portfolio of full-length, human recombinant laminin proteins designed to mimic the native cellular microenvironment. These Biolaminin® substrates offer a biologically relevant matrix that supports the robust expansion, maintenance, and differentiation of various cell types, including pluripotent stem cells and primary cells. By providing an authentic cell-matrix interaction, BioLamina's products enhance cell functionality, improve reproducibility, and streamline the path from basic research to clinical translation. The defined, animal-origin-free nature of these matrices also supports regulatory compliance for advanced therapy medicinal products.
Target Audience
Researchers and developers in academia and industry focused on stem cell biology, regenerative medicine, cell therapy development, and disease modeling.
Features
- Full-length, human recombinant laminin proteins (Biolaminin®) that replicate _in vivo_ cell-matrix interactions.
- Available in various grades: LN (research), MX (translational research), and CTG (Cell Therapy Grade) for seamless progression from discovery to clinical application.
- Supports robust expansion, maintenance, and differentiation of pluripotent stem cells (hESCs, iPSCs) and primary cells.
- Enhances cell functionality, including improved differentiation efficiency, cell maturation, and higher cell yield.
- Batch-to-batch consistency ensures reproducible results and reduces experimental variability.
- Defined and xeno-free composition, critical for clinical compliance and regulatory requirements.
- Compatible with both 2D and 3D cell culture systems, including integration with biomaterials like Biosilk™ for organoid formation.
- Extensive publication record demonstrating efficacy across diverse cell types and applications, including neural, cardiac, hepatic, and ocular cells.